25Feb 2023
Approvals in 2022: overall survival, dose optimization, new approvals and beyond

Approvals in 2022: overall survival, dose optimization, new approvals and beyond

In 2022, the FDA approved a range of new drugs and biologic agents for the treatment of various cancers, including lymphomas, leukemias, multiple myeloma, melanoma, prostate cancer, hepatocellular carcinoma, and cholangiocarcinoma. Immunotherapy was a particularly active area with approvals of five new monoclonal or bispecific antibodies. The FDA Oncology Center of Excellence focused on ongoing monitoring of the Accelerated Approval programme and drug dose optimization. The approved drugs included target program molecules, immuno-therapeutics, gene therapy, and radio-pharmaceutical.

  • #oncology

Like

Save

Share